NOD1 Cancer Research Results

NOD1, Nucleotide-binding oligomerization domain-containing protein 1: Click to Expand ⟱
Source:
Type:

NOD1 is a cytosolic pattern-recognition receptor in the NOD-like receptor family. It detects bacterial peptidoglycan fragments, particularly γ-D-glutamyl-meso-diaminopimelic acid, and signals mainly through RIPK2, activating NF-κB and MAPK pathways. It can also influence autophagy, inflammation, antimicrobial defence and cell death.
Scientific Papers found: Click to Expand⟱
6848- EVO,    Evodiamine: A Extremely Potential Drug Development Candidate of Alkaloids from Evodia rutaecarpa
- Review, Nor, NA
AntiTum↑, In recent years, the antitumor, cardioprotective, anti-inflammatory, and anti-Alzheimer’s disease effects of EVO have been reported.
cardioP↑,
Inflam↓,
TumCP↓, EVO exerts antitumor effects by inhibiting tumor cell activity and proliferation, blocking the cell cycle, promoting apoptosis and autophagy, and inhibiting the formation of the tumor microvasculature.
TumCCA↑,
Apoptosis↑,
TumAuto↑,
BioAv↓, However, EVO has poor solubility and low bioavailability.
toxicity↑, Current research found that EVO could have toxic effects, such as hepatotoxicity, nephrotoxicity, and cardiac toxicity.
NF-kB↓, SMMC-7721 and HepG2 Cells Inhibiting NOD1 to suppress NF-κB and MAPK activation
MAPK↓,
NOD1↓,
p‑Akt↓, HepG2, SMMC-7721 and H22 cell; H22 xenograft mouse model Decreased p-Akt levels activated by SC79, which led to the increase of bax/bcl-2 and cleaved-caspase3.
BAX↑,
cl‑Casp3↑,
γH2AX↑, TPC-1 and SW1736 human thyroid carcinoma cells Increased the protein levels of γH2AX and cleaved PARP, and ROS production
cl‑PARP↑,
ROS↑,
BBB↑, EVO can passively diffuse through the single-cell blood-brain barrier.
neuroP↑, It showed a concentration-dependent neuroprotective effect on PC12 cells injured by MPP+ or H2O2, indicating its potential as a neuroprotective drug
BioAv↑, nanoparticles had a size of 183.23 nm and showed better absorption than free EVO in the entire gastrointestinal tract. The relative bioavailability was 4.58 times that of free EVO.

7874- isoO,    Isoorientin protects lipopolysaccharide-induced acute lung injury in mice via modulating Keap1/Nrf2-HO-1 and NLRP3 inflammasome pathways
- in-vivo, Nor, NA
*ROS↓, ISO also signally decreased oxidative stress and suppressed the content of interleukin-6 (IL-6) in BALF
*IL6↓,
*NRF2↑, ISO significantly promoted the expression of nuclear factor E2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1) and down-regulated kelch-like ECH-associated protein 1 (Keap1).
*HO-1↑,
*Keap1↓,
*NOD1↓, Simultaneously, it suppressed the over-expression of NOD-, LRR- and pyrin domain-containing 3 (NLRP3), caspase-1, apoptosis-associated speck-like protein containing a CARD (ASC) and pro-inflammatory cytokines interleukin IL-1β (
*NLRP3↓,
*Casp1↓,
*ASC↓,
*IL1β↓,
*Apoptosis↓, inhibited the expression of apoptotic related proteins induced by LPS challenge


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NOD1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Cell Death(tgid=5) ⓘ

p‑Akt↓, 1,   Apoptosis↑, 1,   BAX↑, 1,   cl‑Casp3↑, 1,   MAPK↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Migration(tgid=13) ⓘ

TumCP↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   cardioP↑, 1,   neuroP↑, 1,   toxicity↑, 1,  
Total Targets: 21

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

NOD1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

HO-1↑, 1,   Keap1↓, 1,   NRF2↑, 1,   ROS↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Casp1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1,   IL1β↓, 1,   IL6↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  
Total Targets: 12

Scientific Paper Hit Count for: NOD1, Nucleotide-binding oligomerization domain-containing protein 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1533  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page